The company has expanded geographically into new markets including South America
US-based Verdesian Life Sciences, a leading platform that develops patented biological, nutritional, fertilizer enhancers, seed treatment and inoculant technologies for high-value specialty crops, row crops, and turf and ornamental markets, has recently announced that it has entered into a definitive stock purchase agreement with funds managed by AEA Investors LP (AEA). Verdesian’s management team, including President and CEO Kenny Avery, will continue to lead the company following the close of the transaction.
Verdesian has grown into a market leader in Nutrient Use Efficiency by executing on a multi-pronged go-to-market strategy, completing six add-on acquisitions, and developing best-in-class products. The company has expanded geographically into new markets, including South America, and has filed more than 290 patents since 2014. With more than 240 employees around the world, a diverse portfolio of plant nutrient offerings and a stronger financial foundation to scale the business, Verdesian is poised for its next phase of growth.
“AEA is the right partner to help us continue scaling Verdesian and doing what we do better than anyone else: offering Nutrient Use Efficiency technologies for growers all over the world,” said Avery. “With AEA, we are gaining a global partner who recognizes the potential of our products and will support our growth, both organically and through strategic investments, in North America and around the world. We are proud of what we have accomplished since our founding and have had a very successful partnership with Paine Schwartz. Looking ahead, we are excited to work with AEA as we continue to provide critical products to farmers that increase their productivity, profitability and ability to do so sustainably.”
